Your Diabetes Drug Might Already Be Lowering Your Gout Risk

If you have type 2 diabetes and gout, you might already be taking a medication that does both jobs at once. Sodium-glucose cotransporter-2 inhibitors, better known as SGLT2 inhibitors or by brand names like Jardiance (empagliflozin) and Farxiga (dapagliflozin), were designed to lower blood sugar. Researchers have since discovered they also drop serum uric acid by roughly 0.6 to 1.5 mg/dL, and a new wave of 2026 studies suggests that reduction translates into fewer gout flares and less need for allopurinol.

That’s a big deal. Roughly 9 million Americans live with gout, and type 2 diabetes and gout overlap constantly. Both conditions share insulin resistance as a common driver. If you have both, your doctor is probably juggling diabetes meds, urate-lowering therapy, anti-inflammatories, and maybe blood pressure drugs on top. A single pill that chips away at two problems at once sounds almost too convenient, but the data behind it keeps growing.

What SGLT2 Inhibitors Actually Do

SGLT2 inhibitors work in the kidneys. Normally, your kidneys filter glucose from your blood and reabsorb it back into your bloodstream through a transporter protein called SGLT2 in the proximal tubule. Block that transporter, and your kidneys dump excess glucose into your urine instead of hanging onto it. Blood sugar goes down. You lose a few hundred calories a day through that spilled sugar.

Here is where it gets relevant for gout. That same segment of the kidney tubule also handles uric acid reabsorption. When glucose floods the tubular lumen, it competes with uric acid for transport through a protein called GLUT9 (glucose transporter 9). Less uric acid gets reabsorbed. More gets flushed out in urine. Serum urate drops.

This is not some hypothetical mechanism. The urate-lowering effect shows up consistently across trials. In the DAPA-HF trial, dapagliflozin reduced uric acid by about 1.1 mg/dL compared with placebo at eight months. Across the broader SGLT2 inhibitor class, reductions of 0.6 to 1.5 mg/dL are typical. For context, that is roughly half the effect of a standard dose of allopurinol, which usually lowers urate by about 2 to 3 mg/dL. Not a replacement, but not nothing either. If you are wondering how urate-lowering medications compare, see our breakdown of whether you can ever stop taking gout medication.

The 2026 Evidence: From Labs to Real Patients

Two major studies published in 2026 moved this conversation from “interesting lab finding” to “clinically meaningful.”

The first came out in Diabetes, Obesity and Metabolism in June 2026. Researchers used the Korean National Health Insurance Service database to compare over 20,000 matched pairs of people with type 2 diabetes starting either an SGLT2 inhibitor or a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor), a different diabetes drug class with no known urate-lowering effect. The SGLT2 inhibitor group had a 20% lower risk of developing gout, with an incidence rate of 2,793 versus 3,347 per 100,000 person-years. The hazard ratio was 0.80 (95% CI 0.76 to 0.84).

The team also ran a Mendelian randomization analysis using genetic variants in the SLC5A2 gene (which codes for the SGLT2 protein) as a proxy for SGLT2 inhibition. The genetic evidence pointed in the same direction: genetically predicted SGLT2 inhibition was associated with substantially lower gout risk (odds ratio 0.10 per 1-standard deviation decrease in HbA1c; 95% CI 0.017 to 0.463). Genetic evidence of this type helps rule out the possibility that the observational findings are just confounded by healthier patients getting one drug over another.

The second study, published in Diabetes Care and summarized in June 2026, used a target trial emulation framework with data from British Columbia, Canada. It included 26,739 adults with both gout and type 2 diabetes. People starting SGLT2 inhibitors were 38% less likely to start allopurinol compared with those starting DPP-4 inhibitors (hazard ratio 0.62; 95% CI 0.52 to 0.73). They also used fewer gout rescue medications:

• High-dose glucocorticoids down 22% (rate ratio 0.78)
• Nonsteroidal anti-inflammatory drugs (NSAIDs) down 15% (rate ratio 0.85)
• Colchicine down 13% (rate ratio 0.87)

The reduction in steroid and NSAID use matters beyond convenience. People with diabetes and gout often also have chronic kidney disease or cardiovascular disease, where NSAIDs can cause kidney damage and steroids can spike blood sugar. Fewer flares means fewer of those problematic rescue prescriptions.

The benefit was even more pronounced in people already taking diuretics at baseline, a group that typically struggles with higher uric acid levels. SGLT2 inhibitors provide some of the same fluid-offloading effect as diuretics without the uric acid penalty.

The SAVE-Care Trial: First RCT in People With Gout

All the evidence so far has come from post hoc analyses of cardiovascular and diabetes trials, plus observational cohort studies. No randomized controlled trial had ever tested an SGLT2 inhibitor specifically in people with gout. That changed in July 2026, when Massachusetts General Hospital launched the SAVE-Care trial (NCT06674109), funded by the National Institutes of Health.

SAVE-Care is a double-blind, placebo-controlled Phase 4 trial enrolling 60 people with gout and hyperuricemia. Participants are randomized 2:1 to empagliflozin 10 mg daily or placebo for 12 weeks. The primary endpoint is change in serum urate. Secondary endpoints include high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and gout flare rates. Results are expected by early 2028.

The trial is small, but it is a start. If empagliflozin lowers urate by 1.5 mg/dL or more in this population, as the investigators hypothesize, SGLT2 inhibitors could become a legitimate add-on or even alternative for certain people with gout, particularly those who also have diabetes, heart failure, or chronic kidney disease where these drugs are already recommended.

What This Means for You

If you have type 2 diabetes and gout, and you are not already on an SGLT2 inhibitor, this is worth bringing up at your next appointment. These drugs are already recommended for many people with type 2 diabetes who also have cardiovascular disease, heart failure, or chronic kidney disease, regardless of gout. If you fall into one of those groups, the gout benefit is a bonus on top of an indication you may already meet.

But do not run to your doctor demanding a prescription solely for gout. The evidence, while growing, is not yet strong enough to support using SGLT2 inhibitors as standalone gout treatment. No guideline recommends them for gout alone, and the SAVE-Care trial has not reported results. They do not lower urate as much as allopurinol or febuxostat, and they carry their own risks, including genital yeast infections, dehydration, and a rare but serious condition called euglycemic diabetic ketoacidosis.

Also, these drugs are expensive without insurance. Brand-name empagliflozin and dapagliflozin can run $550 to $620 per month in the United States. Generic versions are not yet widely available.

The Kidney Connection

Gout and kidney disease are tangled together. About half of people with gout have some degree of kidney impairment, and reduced kidney function is one of the strongest risk factors for both high uric acid and gout flares. SGLT2 inhibitors are among the few diabetes drugs that are proven to slow kidney disease progression, which makes them an attractive option if you have both conditions. For more on this overlap, read about what happens when kidney failure changes your gout treatment.

That said, these drugs are not for everyone with kidney problems. If your estimated glomerular filtration rate (eGFR) is below a certain threshold, the glucose-lowering effect diminishes, though the kidney and cardiovascular benefits may persist at lower eGFR levels depending on the specific drug. Your doctor will check your kidney function before starting and periodically while you take it.

The mechanism also matters for kidney stone risk. SGLT2 inhibitors increase uric acid excretion in urine, which could theoretically raise the risk of uric acid kidney stones. In practice, this has not shown up as a significant safety signal in large trials, but it is something to discuss with your doctor if you have a history of kidney stones.

How SGLT2 Inhibitors Compare to Other Gout Treatments

To put the urate-lowering effect in perspective:

• Allopurinol typically lowers serum urate by 2 to 3 mg/dL and is the first-line standard.
• Febuxostat lowers urate by roughly 3 to 4 mg/dL but carries a boxed warning for cardiovascular death. If cardiovascular risk is a concern for you, our article on gout crystals in your arteries explains the connection.
• SGLT2 inhibitors lower urate by about 0.6 to 1.5 mg/dL as a secondary effect.

For someone with urate at 8.5 mg/dL, a 1.2 mg/dL drop from an SGLT2 inhibitor gets them to 7.3, still above the 6.0 mg/dL target that the American College of Rheumatology recommends. It helps, but it probably does not replace allopurinol if your urate is significantly elevated. What it might do is reduce the dose of allopurinol you need, or reduce the frequency of flares even if you are already on urate-lowering therapy.

Some people with gout and diabetes are on multiple medications that push uric acid up. Diuretics like hydrochlorothiazide and furosemide are common culprits behind rising uric acid. So is low-dose aspirin, though the evidence there is more nuanced. If your doctor can switch you from a diuretic to an SGLT2 inhibitor for blood pressure or fluid management, you might remove a gout trigger while adding a gout protector. That is the kind of medication simplification that can make a real difference over time.

Common Questions About SGLT2 Inhibitors and Gout

Can an SGLT2 inhibitor replace my allopurinol?

Not right now, based on the evidence. SGLT2 inhibitors lower urate by 0.6 to 1.5 mg/dL, which is usually not enough to reach the target of below 6 mg/dL on its own if your urate is significantly elevated. Think of it as a helpful add-on, not a substitute. If you are already on allopurinol and your urate is well controlled, an SGLT2 inhibitor might give you extra protection against flares. Do not stop your allopurinol without talking to your doctor.

How long does it take for uric acid to drop after starting an SGLT2 inhibitor?

The urate-lowering effect starts quickly, within the first few weeks of treatment, and is usually stable by about 8 to 12 weeks. In the DAPA-HF trial, the difference between dapagliflozin and placebo was evident at the first measurement and persisted throughout the trial. Do not expect a dramatic single-digit drop; this is a gradual, modest reduction.

Are SGLT2 inhibitors approved for gout treatment?

No. The U.S. Food and Drug Administration has approved SGLT2 inhibitors for type 2 diabetes, heart failure, and chronic kidney disease, but not for gout or hyperuricemia. Any use for gout is off-label. That does not mean it is inappropriate; doctors prescribe medications off-label all the time when evidence supports it. Just know that gout is not yet an official indication, and it probably will not be until a dedicated clinical trial like SAVE-Care produces positive results.

What are the side effects I should watch for?

The most common side effects are genital yeast infections and urinary tract infections, especially in women. Staying hydrated helps. There is also a risk of dehydration and low blood pressure, particularly in older adults or people taking diuretics. The most serious rare risk is euglycemic diabetic ketoacidosis, a dangerous buildup of ketones that can happen even when blood sugar is not extremely high. Watch for symptoms like nausea, vomiting, abdominal pain, confusion, and unusual fatigue.

If I don’t have diabetes, can I take an SGLT2 inhibitor for gout?

At this point, no. SGLT2 inhibitors are not approved for people without diabetes, heart failure, or kidney disease, and no study has tested them as a standalone gout treatment in people without those conditions. The SAVE-Care trial enrolls people with gout regardless of diabetes status, but until those results are in, there is no basis for using these drugs solely for gout. If you have gout without diabetes, your proven options remain allopurinol, febuxostat, and lifestyle modifications.

Will this drug interact with my other gout medications?

SGLT2 inhibitors have not shown significant drug interactions with allopurinol, febuxostat, colchicine, or NSAIDs. But if you are taking diuretics, the combination can increase the risk of dehydration and low blood pressure. Your doctor may need to adjust the diuretic dose. As a rule, make sure every prescriber you see knows the full list of medications and supplements you take.

The Bottom Line

SGLT2 inhibitors are not a gout miracle drug. They lower urate modestly, they are expensive, and they are not approved for gout as a standalone treatment. But if you have type 2 diabetes, heart failure, or chronic kidney disease alongside your gout, these medications might already be on your radar, and the gout benefit is one more reason to consider them. They reduce flares, cut down on the need for steroids and NSAIDs, and protect your heart and kidneys at the same time.

The SAVE-Care trial will give us the first real randomized data in people with gout specifically. Until then, the best move is to talk to your doctor about whether an SGLT2 inhibitor fits your overall health picture. If it does, you might be treating your diabetes and your gout with the same pill.

Reviewed by the GoutSavvy Editorial Team